Rheumatology.net

Rheumatology Xagena

Stimulators of the soluble guanylate cyclase ( sGC ) have recently been shown to inhibit transforming growth factor-beta ( TGF-beta ) signalling. Researchers aimed to demonstrate that Riociguat ( ...


Enhanced cardiovascular risk in ankylosing spondylitis provides a strong rationale for early therapeutical intervention. In view of the proven benefit of statins in atherosclerotic vascular disease, a ...


Patients with rheumatoid arthritis and carotid artery plaques have increased risk of acute coronary syndromes. Statin treatment with low density lipoprotein cholesterol ( LDL-c ) goal  less than or eq ...


The results of several new sub-analyses of the phase IIIb AVERT ( Assessing Very Early Rheumatoid arthritis Treatment ) trial that investigated the use of Abatacept ( Orencia ) plus Methotrexate ( MTX ...


Rheumatoid arthritis is associated with increased cardiovascular morbidity and mortality attributed to traditional cardiovascular risk factors and/or the chronic systemic inflammation. Researchers ...


Etanercept ( Enbrel ) has been widely applied in the treatment of ankylosing spondylitis ( AS ). Previous meta-analyses have focused on comparing the differences in clinical outcomes between Etanercep ...


A study has evaluated the efficacy and safety of Adalimumab ( Humira ) in patients with juvenile idiopathic arthritis ( JIA ). Baseline demographic and clinical characteristics and disease activity ...


A study has investigated whether use of Adalimumab ( Humira ) decreases the frequency of attacks of anterior uveitis in patients with ankylosing spondylitis. Consecutive patients with ankylosing sp ...


High body mass index ( BMI ) is associated with increased risk of osteoarthritis ( OA ) and reduced risk of fragility fracture. However, the relationship between fragility fracture and osteoarthritis ...


Positive results from a phase 3 trial of investigational drug Sarilumab in rheumatoid arthritis ( RA ) patients who were inadequate responders to Methotrexate ( MTX ) therapy were presented at the Eur ...


The aim of the study was to assess efficacy and safety of TNF-alpha antagonists ( anti-TNF ) in a cohort of patients with juvenile idiopathic arthritis ( JIA ) who began treatment under 4 years old an ...


The European Commission ( EC ) has granted a licence extension for Enbrel ( Etanercept ) in the treatment of adult patients with severe non-radiographic axial spondyloarthritis ( nr-axSpA ). Non-ra ...


Results of the phase III POSTURE study evaluating Apremilast ( Otezla ), the oral, selective inhibitor of phosphodiesterase 4 ( PDE4 ), in patients with active ankylosing spondylitis. The Apremilast a ...


A new study presented at the European League Against Rheumatism Annual Congress ( EULAR 2014 ) has shown a significantly increased risk of myocardial infarction in patients with Sjögren's syndrome ( S ...


Data presented at the European League Against Rheumatism Annual Congress ( EULAR 2014 ) have demonstrated the possibility of using biomarkers ( developed from whole blood gene expression profiles ) in ...


Conclusive data about cardiovascular toxicity of nonsteroidal anti-inflammatory drugs ( NSAIDs ) are sparse. It has been hypothesized that regular NSAID use is associated with increased risk for cardi ...


Biological agents offer good control of rheumatoid arthritis, but the long-term benefits of achieving low disease activity with a biological agent plus Methotrexate or Methotrexate alone are unclear. ...


Two-year results from the ORAL Start study were published in The New England Journal of Medicine ( NEJM ). ORAL Start is a 24-month phase 3 study in patients with moderately to severely active rheumat ...


Decernotinib ( VX-509 ) is an oral selective JAK3 inhibitor being evaluated for the treatment of rheumatoid arthritis ( RA ). This was a 24-week, randomized, placebo-controlled, double-blind, phase 2 ...


Tofacitinib ( Xeljanz ) is an oral Janus kinase ( JAK ) inhibitor for the treatment of rheumatoid arthritis ( RA ). Phase 2, phase 3, and open-label long-term extension ( LTE ) studies have descri ...


Mavrilimumab and Sifalimumab have met their primary endpoints in respective phase II studies, demonstrating further pipeline progress in core therapeutic areas. Mavrilimumab, an investigational mon ...


The FDA ( Food and Drug Administration ) has approved Otezla ( Apremilast ), a oral selective inhibitor of phosphodiesterase 4 ( PDE4 ), for the treatment of adult patients with active psoriatic arth ...


The aim of a study was to describe the long-term safety and efficacy profile of Tofacitinib ( Xeljanz ) in patients with moderate to severe active rheumatoid arthritis. Data were pooled from 2 open ...


The aim of a study was to assess long-term tolerability, safety, and efficacy of subcutaneous ( SC ) Abatacept ( Orencia ) in Methotrexate-refractory patients with rheumatoid arthritis. The phase I ...


Osteoarthritis is a leading cause of disability, characterized by the destruction of cartilage tissue in joints, but there is a lack of effective therapies because the underlying molecular causes have ...


Plasmacytoid dendritic cells have been implicated in the pathogenesis of systemic sclerosis through mechanisms beyond the previously suggested production of type I interferon.Researchers have isolated ...


Rheumatoid arthritis is a heterogeneous chronic disease, and no therapeutic agent has been identified which is universally and persistently effective in all patients. Researchers have investigated t ...


The 18-month efficacy of a single course of Rituximab ( MabThera, Rituxan ) as compared with conventional immunosuppression with Cyclophosphamide followed by Azathioprine in patients with severe ( org ...


Many patients with psoriasis develop psoriatic arthritis, a chronic inflammatory disease that afflicts peripheral synovial, axial, and entheseal structures. The fully human monoclonal antibody Ustekin ...


The vascular and gastrointestinal effects of non-steroidal anti-inflammatory drugs ( NSAIDs ), including selective COX-2 inhibitors ( coxibs ) and traditional non-steroidal anti-inflammatory drugs ( t ...


Orencia ( Abatacept ) SC ( subcutaneous ) and IV ( intravenous ) is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and im ...


The Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion recommending a variation to the terms of the marketing authorisation for the medicinal product RoActemra ( To ...


The Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion recommending a variation to the terms of the marketing authorisation for the medicinal product MabThera ( Rit ...


Eli Lilly has announced that it will discontinue the phase 3 rheumatoid arthritis ( RA ) program for Tabalumab, an anti-BAFF ( B cell activating factor ) monoclonal antibody, due to lack of efficacy. ...


the Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion recommending a variation to the terms of the marketing authorisation for the medicinal product Cimzia ( Certo ...


Dipeptidyl peptidase-4 inhibitors ( DPP4i ), such as Linagliptin, Saxagliptin, and Sitagliptin, are oral glucose-lowering drugs for type 2 diabetes mellitus ( T2DM ). DPP4 is a transmembrane glycoprot ...


Celgene has announced results of phase II trial ( BCT-001 ) on Apremilast, a oral targeted inhibitor of phosphodiesterase 4 ( PDE4 ), in patients with Behçet’s disease.These data have showed that sign ...


Celgene has announced results of its long-term phase III study on Apremilast, a targeted inhibitor of phosphodiesterase 4 ( PDE4 ), in systemic or biologic DMARD-naïve psoriatic arthritis patients.PAL ...


Eli Lilly and Incyte have announced 52-week efficacy and safety data from the open-label, long-term extension of the Phase 2b JADA study of Baricitinib in patients with active rheumatoid arthritis. Ba ...


A team of researchers has analysed the association between alcohol intake and incidence of rheumatoid arthritis in women. The prospective study has used data from The Swedish Mammography Cohort, a ...


Even with optimal disease-modifying treatment and good control of disease activity, persistent pain due to structural damage is common in people with inflammatory arthritis and therefore additional tr ...


Pain management is a high priority for patients with rheumatoid arthritis. Despite deficiencies in research data, neuromodulators have gained widespread clinical acceptance as adjuvants in the managem ...


Pain management is a high priority for patients with rheumatoid arthritis. Muscle relaxants include drugs that reduce muscle spasm ( for example benzodiazepines such as Diazepam ( Valium ), Alprazolam ...


Pegloticase ( Krystexxa ) is a potential new treatment option for patients with chronic gout intolerant to other urate-lowering therapies.An analisys has been performed to investigate safety ( adverse ...


Patients suffering from two serious autoimmune disorders which cause muscular inflammation are at increased risk of developing cardiovascular disease, says a group of Montreal researchers. Christian A ...


Rheumatoid arthritis patients who failed to respond to initial treatment with Rituximab ( MabThera, Rituxan ) ( a chimeric monoclonal antibody against the protein CD20 ) can still be successfully re-t ...


To manage the painful and incapacitating symptoms of rheumatoid arthritis ( RA ), a chronic, inflammatory joint disease, the majority of patients rely on disease-modifying antirheumatic drugs ( DMARDs ...


B cells, precursors of autoantibody-secreting cells, have emerged as promising new therapeutic targets in autoimmune diseases, including rheumatoid arthritis. In particular, B cell depletion with the ...


B cells, precursors of autoantibody-secreting cells, have emerged as promising new therapeutic targets in autoimmune diseases, including rheumatoid arthritis. In particular, B cell depletion with the ...


A chronic autoimmune disease, rheumatoid arthritis is characterized by persistent inflammation of the synovial membrane and progressive joint destruction. Beyond loss of mobility, sufferers face a hig ...



2000-2014© XAGENA srl - P.IVA: 04454930969 - REA: 1748680 - Tutti i diritti riservati